EGFR and non-small cell lung carcinoma: In this regard, two PROTACs synthetized by using gefitinib as the EGFR binder were able to reduce proliferation of Del19- and L858R-EGFR expressing NSCLC cells, along with the levels of EGFR and the activation of downstream signaling pathways [101].